It is observed in various studies that API treatment induces FOXO3a expression by reducing AKT phosphorylation and then upregulating the expression of p21 and p27, FOXO3a target genes, which inhibits cancer cell proliferation [21]. This evidence concerns the gene AKT1 and cancer.